Aduro BioTech, a Berkeley, CA-based clinical-stage immunotherapy company with a platform technology for therapeutic and prophylactic vaccines for cancer and infectious diseases, has completed a $19.25m Series B equity financing.
Investors include existing shareholders and Morningside Ventures.
In conjunction with the close, Ms. Stephanie O’Brien of Morningside, has joined Aduro’s Board of Directors.
As stated by chairman and CEO Stephen Isaacs, the company intends to use the capital to:
– advance its lead cancer vaccine, CRS-207, into a Phase 2 clinical trial in pancreatic cancer;
– support initial clinical development of CRS-207 for other indications;
– support preclinical development of therapeutic vaccines for prostate cancer and melanoma;
– support preclinical development of prophylactic vaccines for malaria and tularemia.